Please login to the form below

Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Sanofi acquired rights to sutimlimab as part of its $11.6bn takeover of Bioverativ last year under former CEO Olivier Brandicourt, and has been billed as one of the most promising

Latest news

Dupixent drives Sanofi again, but other new drugs are lagging

There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed
EMA clears Novo Nordisk’s long-acting haemophilia A drug

Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
Hudson named Brandicourt’s successor as Sanofi’s CEO

He also bolstered the company’s pipeline with acquisitions of Ablynx and Bioverativ for 3.9bn and $11.6bn, respectively, building a franchise in rare blood diseases, but missed out to
Bicycle Therapeutics looks to raise $86m with IPO

The company has research collaborations with AstraZeneca in respiratory, cardiovascular and metabolic disease, Bioverativ in non-malignant haematology indications, including haemophilia and with Oxurion in ophthalmology.
Sobi shows strong growth despite haemophilia competition

countries. Marketing rights to the drugs in the US, Canada and Japan are held by Bioverativ, which was acquired last year by Sanofi.

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... only with its rare disease focus but also enhances its portfolio of products for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Industry appointments

Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Lead Copywriter: Competitive

Medical Editor: Competitive

Healthcare Account Director: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Account Director – Creative Healthcare Communications: Competative

Healthcare Senior Account Manager: Competitive

PMHub

Add my company

Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...